AZN vs LLY: fair value comparison
AstraZeneca PLC and Eli Lilly and Company · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AZN currently sits closer to the top of our discount ranking. AZN carries the stronger quality grade.
| AZN | LLY | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $156.93 | $1,149.36 |
| 12-month range | $156.93–$202.39 | $862.86–$1,160.00 |
| Sector rank | #6 of 113 Healthcare | #11 of 113 Healthcare |
| Quality grade | B | D |
| Leverage | Moderate | High |
| Margin trend | Expanding | Expanding |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | Undervalued | — |
| 52-week position | The bottom quarter | The top quarter |
Full single-stock breakdowns: AZN fair value analysis · LLY fair value analysis